Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients

NCT00627146 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: ChAgly CD3
DRUG: Placebo

Sponsor

Universitair Ziekenhuis Brussel

Collaborators

[object Object]
[object Object]
[object Object]